A new framework for measuring the value of Parkinson’s treatments

As researchers work on treatments that could potentially slow the progression of Parkinson’s, there is a practical problem: how do we measure whether these treatments are really worth their cost? A new study published in PharmacoEconomics reviewed existing economic models used to evaluate Parkinson’s treatments and found important gaps. Many current models focus mainly on movement symptoms and later stages of the disease. They do not fully capture the wide range of symptoms and difficulties that people experience throughout Parkinson’s. Parkinson’s is more than movement symptoms The researchers argue that future models should include both motor and non motor symptoms, such as sleep problems, depression, anxiety, cognitive changes, fatigue and pain. They should also consider how Parkinson’s affects independence, caregivers, work and social care. This is particularly important for a disease modifying treatment. Unlike a treatment that simply controls symptoms, a disease modifying therapy would aim to slow the underlying progression of Parkinson’s. The benefits might therefore take years to become clear. Slowing progression could mean staying independent for longer, delaying disability and reducing the need for care and support. A better way to model Parkinson’s The researchers propose a model that follows people from the early stages of Parkinson’s through the later stages of the disease. It would track changes in symptoms and disease progression more continuously, rather than simply moving people between broad disease stages. The model would also take individual differences into account, because Parkinson’s does not progress in the same way for everyone. The study does not show that a disease modifying treatment currently exists. Instead, it provides a framework for how future treatments should be evaluated. The key message is that the value of a Parkinson’s treatment should not be measured only by whether it improves symptoms today. If a treatment can slow progression, its biggest benefits may be seen years later through greater independence, fewer complications and less need for care.